仁和药业:公司联营企业成都瑞沐的创新药RM301B已完成一期临床试验,目前在制定二期临床方案
Group 1 - The core point of the article is that Renhe Pharmaceutical's joint venture Chengdu Ruimu has made significant progress in the clinical trial of its innovative drug RM301B, which is currently in the process of developing a phase II clinical plan [1][3] - RM301B is a groundbreaking ophthalmic drug developed by Chengdu Ruimu, a high-tech biopharmaceutical company founded by overseas returnees, focusing on new technologies and products in ophthalmology [3] - The company is in negotiations regarding whether it will exclusively market RM301B and other new products, which, if successful, is expected to have a positive impact on the company's performance [1][3]